Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,806.40
(
0.76%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.52
(
0.33%
)
Bitcoin
81,086.01
(
0.04%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 129084

Wednesday, 08/01/2012 4:41:26 PM

Wednesday, August 01, 2012 4:41:26 PM

Post# of 257566
NIH study elucidates the MoA of Daclizumab in MS:

http://www.nih.gov/news/health/aug2012/ninds-01.htm

Daclizumab is being jointly developed by ABT and BIIB. It is in phase-3 for MS with an expected completion date of Mar 2014 (http://www.clinicaltrials.gov/ct2/show/NCT01064401 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today